Suppliers / zhejiang jiuzhou pharmaceutical

zhejiang jiuzhou pharmaceutical

China 603456.SS Updated 9 July 2026

zhejiang jiuzhou pharmaceutical is an API manufacturer based in China. It holds 8 active US drug master files across a filed portfolio of 11 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 23 August 2024 as NAI.

8
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 23 August 2024 NAI US FDA
  • 13 September 2018 VAI US FDA
  • 23 January 2016 VAI US FDA
  • 24 October 2013 OAI US FDA
  • 21 April 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3003744377

What they file, and where

Molecule Regulators Docs
Imatinib SFDA (Saudi Arabia), US FDA 2
Sulfadimethoxine US FDA 2
Acyclovir US FDA 1
Gefitinib US FDA 1
Gliclazide SFDA (Saudi Arabia) 1
Imatinib Mesilate SFDA (Saudi Arabia) 1
Oxcarbazepine US FDA 1
Sildenafil US FDA 1
Sitagliptin US FDA 1
Sulfasalazine SFDA (Saudi Arabia) 1
Show all 11 molecules on file
Tenofovir Disoproxil SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Abacavir contract manufacturing Acyclovir API Carbamazepine contract manufacturing Dexketoprofen contract manufacturing Duloxetine contract manufacturing Gliclazide contract manufacturing Meropenem contract manufacturing Oxcarbazepine contract manufacturing Paroxetine contract manufacturing Sildenafil API Sitagliptin contract manufacturing Venlafaxine contract manufacturing
Show 1 more molecule pages
Tenofovir Disoproxil API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. zhejiang jiuzhou pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 23 August 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates